VAXART (VXRT)
$0.48
0.01 (1.92%)
VXRT Stock Quote Delayed 30 Minutes
Vaxart Is Another Risky Biotech Stock to Avoid Right Now
VRXT stock is highly overvalued. Investors are holding out for its Covid-19 vaccine, but it may not be approved in time to boost shares.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$0.47
Market Cap
106.87M
PE Ratio
-1.21
EPS
-0.3947
Volume (Avg. Vol.)
2.35M
Day's Range
$0.46 - $0.48
52-Week Range
$0.45 - $1.41
Dividend & Yield
N/A (N/A)
VXRT Stock Predictions, Articles, and VAXART News
The Bull Thesis for VXRT Stock is Questionable at Best
If Vaxart were to fulfill its promise a lot would have to transpire in its favor. Here's why you shouldn't expect that to happen.
VXRT Stock: The Big FDA News Sending Vaxart Shooting Higher Today
VXRT stock is bulking up today. The company is getting approval from the FDA regarding its Covid vaccine, allowing for further research.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? All eyes were on hard-hit Nikola stock and growing interest in mental health startups.
Vaxart Stock Has Built-In Value Well Beyond Its Covid Pill
You can buy VXRT stock for the company's tablet-based Covid-19 vaccine, and hold it for Vaxart's other clinical breakthroughs.
Vaxart Is Gaining Relevance, But Its Future Is Still Uncertain
Vaxart may have a second chance at prominence with its Covid-19 vaccine pill. But VXRT stock is still a largely speculative buy.
Don’t Count on a Covid-19 Boost for Vaxart
VXRT stock remains a speculative bet as the company's chance to develop an oral Covid-19 vaccine grows slimmer every day.
New Developments Have Made Vaxart Stock So Much More Attractive
Vaxart recently made a licensing deal, and two research firms issued upbeat assessments of the company, making me more upbeat on VXRT stock.
Watch Out for a Selloff in Vaxart Stock
Vaxart needs a Covid-19 vaccine approved and selling on the market before the established mega-cap names take all the sales.
Vaxart Stock Could Make Another Big Return in the Future
VXRT stock is known to be a fast mover. Any piece of good news could prove to be a multi-bagger for investors who take an early position.
Will the Promise of Avoiding the Needle Pay Off for Vaxart?
VXRT stock just received a buy recommendation and a $13 price target from Jefferies, based on the promise of a oral vaccine instead of a needle.
VXRT Stock: Can Redditors Help Vaxart Power Higher?
Today, VXRT stock is climbing higher on an otherwise red day for the markets, as many speculate retail investors could be behind this rise.
Vaxart Is Still Not Worth Anywhere Near Its Present Price
Vaxart is still not worth today's price. VXRT stock is worth no more than $6, especially if it's going to need another capital raise.
VXRT Stock: Why Redditors Are Betting on a Big Squeeze With Vaxart Today
VXRT stock is on the move as the company received some very bullish coverage from an analyst initiating coverage today.
Bet on a No-Needle Vaccine Strategy with Vaxart
Reimagining Covid-19 vaccines isn't an easy task, but Vaxart is prepared to innovate - and VXRT stock could move higher at any given moment.
Vaxart’s Compelling Story Will Take a Long Time to Play Out
As a company attempting to make oral vaccines, Vaxart has a compelling story. However VXRT stock looks to be many years away from paying off.
With Fading Covid-19 Infections, Vaxart’s Relevance Is Waning
Prior to the vaccination rollout from Vaxart’s competitors, VXRT stock appeared a compelling alternative. That’s no longer the case.
Vaxart Could Still Be a Viable Covid 19 Vaccine Play
VXRT Stock needs to nail the next few studies of its Covid 19 vaccine candidate and prove its thesis to widen its bull case significantly
High Cash Burn Will Push Vaxart Stock Down To $1 Per Share
Vaxart stock is likely headed down 85% towards its cash per share. VXRT stock is not worth much more than $1.00 per share, so expect to see it drop 85%.
It Won’t Take Much for Vaxart Stock to Pop Once Again
This is a risky play, with a catalyst that more likely than not won't pan out. But, if it releases more promising news within the coming months, it could go on yet another parabolic run. Approach VXRT stock cautiously, but as its share price retreats, now may be the time to pounce.
Vaxart’s No-Shot Vaccine Is a Potential Game Changer
VXRT stock is down from its highs, but there's no need to worry, as Vaxart has a unique Covid-19 vaccine and some encouraging clinical data.
